U.S. markets open in 1 hour 52 minutes
  • S&P Futures

    3,335.00
    -48.00 (-1.42%)
     
  • Dow Futures

    26,870.00
    -495.00 (-1.81%)
     
  • Nasdaq Futures

    11,465.25
    -122.75 (-1.06%)
     
  • Russell 2000 Futures

    1,558.00
    -31.00 (-1.95%)
     
  • Crude Oil

    37.70
    -1.87 (-4.73%)
     
  • Gold

    1,894.60
    -17.30 (-0.90%)
     
  • Silver

    24.12
    -0.45 (-1.83%)
     
  • EUR/USD

    1.1741
    -0.0048 (-0.41%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    36.58
    +4.12 (+12.69%)
     
  • GBP/USD

    1.2969
    -0.0072 (-0.55%)
     
  • USD/JPY

    104.2340
    -0.2600 (-0.25%)
     
  • BTC-USD

    13,383.63
    -326.38 (-2.38%)
     
  • CMC Crypto 200

    264.23
    +2.94 (+1.12%)
     
  • FTSE 100

    5,630.49
    -98.50 (-1.72%)
     
  • Nikkei 225

    23,418.51
    -67.29 (-0.29%)
     

Revelation Biosciences Inc. Appoints Jess Roper to Board of Directors

·4 mins read

Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today the appointment of Jess Roper to the Company’s Board of Directors (Board). The addition of Mr. Roper increases the size of the Board to five directors.

"I am excited to join the Revelation Board at this formative time for the Company," said Mr. Roper. "I look forward to collaborating with the leadership team and members of the Board to further Revelation’s mission and bring immunologic therapeutics and diagnostics to patients in need."

"We are pleased to welcome Jess to our Board. With over two decades of life science industry experience Jess brings deep expertise and a strong independent perspective to the director role," said James Rolke, Chief Executive Officer of Revelation. "We look forward to Jess sharing his valuable insights as we approach the initiation of patient enrollment for our first Phase 1 study."

Mr. Roper has considerable financial and audit experience in the sectors of medical device, life sciences, technology, manufacturing, and financial institutions. He currently serves as a Board Member and Audit Chair for Biolase, a publicly traded company that is the global leader in the manufacturing of dental laser systems. Mr. Roper previously served as Senior Vice President and Chief Financial Officer of Dexcom, retiring in 2017 following a fulfilling and rewarding career. During his 12-year tenure, Dexcom transitioned from a pre-revenue privately held medical device company to a multi-national publicly traded entity.

Mr. Roper previously held financial management positions with two other publicly traded companies and one venture funded company. He has played key roles in two initial public offerings, acquisitions/divestitures, and numerous equity and debt financings. Earlier in his career, Mr. Roper was an auditor with PricewaterhouseCoopers, and a bank and information systems examiner with the Office of the Controller of the Currency. He earned a Master of Science in Corporate Accountancy and a Bachelor of Science in Finance. Mr. Roper is a certified public accountant in the state of California.

For more information on Revelation, please visit www.RevBiosciences.com.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx‑99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS‑CoV‑2 infection. An expansion of REVTx‑99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx‑200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx‑501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type, without the need for specialized instrumentation. For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. These risks include, but are not limited to, risks relating to: the timing and success of future development activities for REVTx-99 and expanded indications, REVTx-200, REVDx-501, or any other product candidates; potential indications for which our product candidates may be developed; the potential impact that COVID-19 may have on us, our suppliers, vendors, regulatory agencies, our employees, and the global economy as a whole; and the expected duration over which the Company’s balance will fund us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201015006030/en/

Contacts

Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
and
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com